Fármacos Gastrointestinales/uso terapéutico; Inmunosupresores/uso terapéutico; Enfermedades Inflamatorias del Intestino/tratamiento farmacológico; Fármacos Gastrointestinales/administración & dosificación; Fármacos Gastrointestinales/efectos adversos; Humanos; Inmunosupresores/administración & dosificación; Inmunosupresores/efectos adversos; Interleucinas/antagonistas & inhibidores; Inhibidores de las Cinasas Janus/uso terapéutico; Factor de Necrosis Tumoral alfa/antagonistas & inhibidores

Aminosalicylates; Antibiotics; Apriso; Asacol; Azasan; Azulfidine; Betnesol; Canasa; Cimzia; Colazal; Colocort; Cortenema; Corticosteroids; Cortifoam; Cortiment; Crohn's disease; Cyclosporine; Delzicol; Dipentum; Entocort; Entyvio; Giazo; Hadima; Humira; Imuran; Inflectra; Integrin Receptor Antagonists; Interleukin (Il)-12 and -23 Antagonist; Ixifi; JAK Inhibitor; Janus Kinase Inhibitor; Lialda; Methotrexate; Metoject; Mezavant; Otrexup; Pentasa; Purixan; Rasuvo; Rayos; Remicade; Renflexis; Rowasa; Salazopyrin; Salofalk; Sandimmune; Simponi; Stelara; TNF Inhibitors; TNF inhibitors; Thiopurines; Tysabri; Uceris; VSL; Xeljanz; adalimumab; adverse effects; aminosalicylates; antibacterials; azathioprine; balsalazide; betamethasone; budesonide; certolizumab; corticosteroids; cyclosporine; dosage; drug interactions; efficacy; golimumab; hydrocortisone; inflammatory bowel disease; infliximab; mercaptopurine; mesalamine; mesalazine; methotrexate; natalizumab; olsalazine; prednisone; probiotics; sulfasalazine; tofacitinib; ulcerative colitis; ustekinumab; vedolizumab